Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elgemtumab - MorphoSys/Novartis

X
Drug Profile

Elgemtumab - MorphoSys/Novartis

Alternative Names: LJM-716; NOV-6

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 07 Jul 2021 Memorial Sloan-Kettering Cancer Center completes its phase I trial for Breast cancer (combination therapy, metastatic disease) in USA (NCT02167854)
  • 02 Aug 2017 Novartis completes a phase I trial in Breast cancer and Gastric cancer (combination therapy, metastatic disease) in USA, United Kingdom, Belgium, France, Italy, Netherlands, Spain, Taiwan and South Korea (IV) (NCT01602406)
  • 27 Jan 2017 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease) in South Korea, Italy, USA, United Kingdom, Netherlands, Belgium, France, Spain, Taiwan (IV) (Novartis 20-F filed in 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top